Entrada Therapeutics (TRDA) Accounts Payables (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Accounts Payables of $2.9 million for Q1 2026, up 33.91% year-over-year from $2.2 million in Q1 2025, and up 28.0% quarter-over-quarter from $2.3 million in Q4 2025.
Entrada Therapeutics (TRDA) Accounts Payables (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 33.91% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 33.91% YoY), while the FY2025 annual figure was $2.3 million, down 46.25% from the prior year.
- Accounts Payables for Q1 2026 stood at $2.9 million, up from $2.3 million in the prior quarter.
- The five-year high for Accounts Payables was $6.5 million in Q1 2023, with the low at $752000.0 in Q3 2023.
- The 5-year median for Accounts Payables is $2.5 million (2024), against an average of $2.9 million.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables soared 748.44% in 2022, then sank 60.97% in 2024.
- Entrada Therapeutics' Accounts Payables stood at $6.0 million in 2022, then tumbled by 45.29% to $3.3 million in 2023, then rose by 29.97% to $4.3 million in 2024, then plunged by 46.25% to $2.3 million in 2025, then grew by 28.0% to $2.9 million in 2026.
- Business Quant data shows TRDA's Accounts Payables at $2.9 million in Q1 2026, $2.3 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 3.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.75 Mn |
| Mar 31, 2026 | 2.93 Mn |
| Dec 31, 2025 | 2.29 Mn |
| Sep 30, 2025 | 3.17 Mn |
| Jun 30, 2025 | 1.86 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 4.26 Mn |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Mar 31, 2024 | 2.53 Mn |
| Dec 31, 2023 | 3.28 Mn |
| Sep 30, 2023 | 752,000.00 |
| Jun 30, 2023 | 2.42 Mn |
| Mar 31, 2023 | 6.47 Mn |
| Dec 31, 2022 | 5.99 Mn |
| Sep 30, 2022 | 1.34 Mn |
| Jun 30, 2022 | 4.62 Mn |
| Mar 31, 2022 | 2.93 Mn |
| Dec 31, 2021 | 706,000.00 |
| Sep 30, 2021 | 2.28 Mn |